Boston Scientific (NYSE:BSX) Issues Q4 2019 Pre-Market Earnings Guidance

Boston Scientific (NYSE:BSX) updated its fourth quarter 2019
Pre-Market earnings guidance on Tuesday. The company provided earnings per share guidance of 0.42-0.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.44. The company issued revenue guidance of $2.9-2.9 billion, compared to the consensus revenue estimate of $2.93 billion.Boston Scientific also updated its FY 2019
Pre-Market guidance to 1.55-1.58 EPS.

Several research analysts recently weighed in on BSX shares. Wells Fargo & Co upped their price objective on shares of Boston Scientific from $48.00 to $52.00 and gave the stock an overweight rating in a research report on Monday, December 16th. Raymond James lowered their target price on shares of Boston Scientific from $50.00 to $48.00 and set a strong-buy rating on the stock in a research note on Monday, October 14th. Stephens set a $48.00 target price on shares of Boston Scientific and gave the company a buy rating in a research report on Monday, September 30th. Morgan Stanley boosted their price target on shares of Boston Scientific from $50.00 to $51.00 and gave the stock an overweight rating in a research note on Tuesday, December 17th. Finally, Cowen reissued a buy rating and issued a $52.00 price target on shares of Boston Scientific in a report on Wednesday. One analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $48.62.

Shares of BSX traded up $0.66 during trading hours on Thursday, hitting $43.23. The company had a trading volume of 103,654 shares, compared to its average volume of 5,733,207. Boston Scientific has a 52-week low of $34.35 and a 52-week high of $46.62. The company has a quick ratio of 0.77, a current ratio of 1.14 and a debt-to-equity ratio of 0.99. The stock’s 50 day moving average price is $44.60 and its 200 day moving average price is $42.41. The firm has a market cap of $59.46 billion, a P/E ratio of 29.39, a P/E/G ratio of 2.08 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.01. The business had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.68 billion. Boston Scientific had a return on equity of 23.10% and a net margin of 10.49%. Boston Scientific’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period last year, the company earned $0.35 EPS. On average, research analysts expect that Boston Scientific will post 1.57 EPS for the current fiscal year.

In other news, insider Williamson Scott acquired 250,000 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were purchased at an average price of $0.12 per share, for a total transaction of $30,000.00. Also, EVP Joseph Michael Fitzgerald sold 107,692 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $45.00, for a total transaction of $4,846,140.00. Following the transaction, the executive vice president now directly owns 200,685 shares of the company’s stock, valued at $9,030,825. The disclosure for this sale can be found here. In the last three months, insiders have sold 195,751 shares of company stock valued at $8,680,501. Insiders own 0.66% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Read More: How does a dividend reinvestment plan work?

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with's FREE daily email newsletter.